.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA27_Droxidopa.Droxidopa .Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA27_Droxidopa.Droxidopa| name: | Droxidopa | |
| ATC code: | C01CA27 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 2.6 | L |
| clearance: | 64 | L/hr |
| other parameters in model implementation | ||
Droxidopa is a synthetic amino acid precursor of norepinephrine. It is used as a prodrug to increase norepinephrine concentrations, primarily for the treatment of neurogenic orthostatic hypotension in patients with Parkinson’s disease, multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. It is currently approved for use in several countries, including the United States.
Pharmacokinetic parameters estimated for oral droxidopa use in adults with neurogenic orthostatic hypotension; general adult population with normal hepatic and renal function.